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Acute neurotoxicity in children treated  
for acute lymphoblastic leukaemia  
– a case series and review of literature
Izabela Kranjčec1, Gordana Jakovljević1,2, Nikolina Kranjec3, Ana Tripalo Batoš4, Lana Lončar5
Complications of paediatric acute lymphoblastic leukaemia therapy in a notable number of patients include acute neurotoxicity, 
which presents most often as cerebrovascular disease, infection or a variety of nonspecific neurologic signs and symptoms, as well 
as recognizable clinical- radiological syndromes, due to admistered chemo- and radiotherapy. Although acute neurological events 
are rarely fatal, they usually present as emergency situations, often require treatment postponement and modifications, and can be 
followed by permanent sequelae in the form of epilepsy or cognitive dysfunction. We present three cases of acute neurotoxicity in 
childhood leukaemia patients treated at our department. Based on clinical presentation, laboratory and radiological findings, these 
cerebral events were characterized as ischaemia of the brain, posterior reversible encephalopathy syndrome and brain oedema with 
syndrome of inappropriate secretion of antidiuretic hormone. Timely and appropriate management resulted in complete neuro-
logical recovery in all three patients.
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INTRODUCTION
Acute lymphoblastic leukaemia (ALL), the most common 
childhood malignancy with the overall survival rate of over 
80% worldwide, is nowadays considered a curable disease 
(1). The high cure rates are mainly attributed to rather ag-
gressive, systemic multi-agent chemotherapy, as well as cen-
tral nervous system (CNS) prophylaxis in the form of intrathe-
cal therapy and radiotherapy, although advances in support-
ive care have also added greatly to this success. This intensive 
treatment, however, is not without considerable morbidity. 
Namely, almost all paediatric patients are faced with an in-
fection at some point of disease course but a few experience 
less common complications, including acute and chronic 
neurotoxicity. About 10% of children with ALL are believed 
to suffer from CNS toxicities during treatment (2). Neurologi-
cal complications are divided into two main categories, pri-
mary involvement of the CNS by leukaemia cells, and sec-
ondary, due to leukaemia itself or the treatment (3). Second-
ary neurological problems can further be categorized as 
cerebrovascular events, posterior reversible encephalopathy 
syndrome (PRES), parenchymal atrophy, infection, complica-
tions due to chemo- or radiotherapy, and secondary brain 
tumours (3). Clinical manifestations vary from headaches, 
impaired consciousness to seizures and focal motor deficits, 
and can be quite nonspecific, so accurate diagnosis is made 
based on medical history, specific laboratory testing, electro-
physiological studies and appropriate imaging (4). Standard 
imaging techniques, including computed tomography (CT) 
and magnetic resonance imaging (MRI), are indispensable in 
identifying acute and chronic neurological developments, as 
well as the possible aetiology (5). Despite appropriate diag-
nostic and therapeutic approach, more than 30% of affected 
patients develop permanent sequelae in the form of epi-
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lepsy or mental retardation, so prompt and proper manage-
ment is mandatory (6).
CASE REPORTS
We present three children treated for ALL at our institution, 
who experienced different forms of acute neurotoxicity 
during intensive chemotherapy. Summary of patient char-
acteristics with clinical data and radiological findings is 
shown in Table 1.
Case 1
A 7-year-old girl was diagnosed with high-risk ALL, CNS-
negative. At the end of ALL IC-BFM protocol induction 
(prednisone 60 mg/m²/d, vincristine (VCR) 1.5 mg/m²/d, 
daunorubicin 30 mg/m²/d, L-asparaginase (L-ASP) 5000 IU/
m²/d, methotrexate (MTX) 12 mg IT), she suddenly col-
lapsed following an episode of febrile neutropenia and 
paralytic ileus. Incoherent speech and horizontal nystag-
mus were observed and high blood pressure recorded. In-
travenous diazepam and oral nifedipine were administered, 
and no further attacks were noted but left arm tremor with 
hypotonia and adynamia persisted. Urgent brain MRI re-
vealed ischaemia in vascular supply of the posterior cere-
bral artery (Figure 1), and because of suspected thrombosis 
anticoagulation therapy (enoxaparin) was initiated. Due to 
abnormal electroencephalogram (EEG), antiepileptic thera-
py (levetiracetam, topiramate) was also started. Mild left-
sided paresis gradually disappeared leading to full recovery 
consistent with completely normal brain MRI only one 
month later.
Case 2
An 8-year-old boy who received chemotherapy according 
to the ALL IC-BFM protocol for high-risk ALL, CNS-negative, 
was admitted during re-induction due to febrile neutrope-
nia and electrolyte imbalance. Ten days after the end of the 
first phase re-induction chemotherapy (dexamethasone 10 
mg/m²/d, VCR 1.5 mg/m²/d, doxorubicin 30 mg/m²/d, L-
ASP 10000 IU/m²/d), he developed tonic-clonic seizures 
that were discontinued with parenteral diazepam, while 
prolonged serum electrolyte imbalance was treated ac-
cordingly. Persistent hypertension demanded combined 
therapy (enalapril, propranolol, furosemide). EEG showed 
no abnormalities, brain MRI findings were consistent with 
PRES (Figure 2). Subtle convulsive attacks accompanied by 
TABLE 1. Clinical, diagnostic and therapeutic patients’ characteristics
Patient Case 1 Case 2 Case 3. 
Diagnosis ALL ALL ALL- relapse
Risk group HR HR IR
CNS involvement No No No





























EEG Abnormal Normal Abnormal
















Follow-up MRI Mild cortical atrophy Residual gliosis Calcified microangiopathy
Clinical outcome Complete recovery Complete recovery Complete recovery
ALL = acute lymphoblastic leukaemia; CNS = central nervous system; HR = high risk; IR = intermediate risk; VCR = vincristine; L- asp = L-asparaginase; 
PEG-ASP = pegylated asparaginase; MTX = methotrexate; IT = intrathecal; AET = antiepileptic therapy; LMWH = low molecular weight heparin; AHT = 
 antihypertensive therapy; MRI = magnetic resonance imaging
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hallucinations and somnolence registered in the next few 
days were eventually terminated with an antiepileptic (leve-
tiracetam). Slow but complete neurological recovery was 
observed and brain MRI performed three months later re-
vealed regression of the previous lesion with residual gliosis.
Case 3
A 10-year old girl was treated for late onset, medullary re-
lapse of CNS-negative ALL according to the ALL-REZ BFM 
protocol. The end-phase of initial leukaemia treatment was 
complicated by seizures with normal EEG and brain MRI dis-
playing leukoencephalopathy. During the third chemother-
apy cycle for relapse (dexamethasone 6 mg/m²/d, VCR 1.5 
mg/m²/d, idarubicin 6 mg/m²/d, pegylated asparaginase 
1000 IU/m²/d, MTX/Cytarabine/Prednisone 12/30/10 mg 
intrathecally), she developed two convulsive attacks 
(munching, head and eye deviation), lasting for a few min-
utes, half an hour apart. Parenteral midazolam was adminis-
tered and due to respiratory instability, she was intubated 
and transferred to the Intensive Care Unit. High blood pres-
sure measurements were recorded repeatedly, while serum 
electrolytes and glucose tests were initially in the reference 
range. Antihypertensive (amlodipine) and antiepileptic (le-
vetiracetam, valproic acid) therapy was initiated, while per-
sistent hyponatremia within the syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH) required ample 
electrolyte supplementation. Initial brain CT scan appeared 
to be normal, whereas brain MRI showed posterior segment 
cortical oedema. Left focal EEG abnormalities were record-
ed additionally. Later on, the patient experienced seizures 
on one more occasion, antiepileptic therapy was continued 
and her neurological status was satisfactory. Follow-up 
brain MRI three months later revealed calcified microangi-
opathy with glial scarring in the left parietal and right oc-
cipital lobe (Figure 3). The girl is now recovering from allo-
geneic hematopoietic stem cell transplant.
DISCUSSION
Every organ and system can be adversely affected during 
intensive ALL treatment, but immune and hematologic 
function, gastrointestinal system with liver function fol-
lowed by central and peripheral nervous system seem to be 
damaged most (7). Acute, transient cerebral complications 
appear in up to 10% of children with ALL (6, 8) and they 
were the focus of our interest in this paper. The most com-
mon acute neurotoxicity includes cerebrovascular events, 
presenting as cerebral infarcts and venous thrombosis, and 
infection, mostly meningitis, usually of iatrogenic aetiology 
(9). According to other published papers, methotrexate- 
leukoencephalopathy (MLE) was the most frequent neuro-
logical syndrome (10). PRES, however, is increasingly more 
often recognized as the leading acute cerebral complica-
tion (6). Metabolic disturbances must also be considered 
among the main causes of acute CNS disease. These dis-
crepancies in reported frequencies might be a result of di-
verse categorization of toxic neurological events and differ-
ent level of health care among countries. None of our cases 
included infection, but cerebrovascular manifestation, PRES 
and leukoencephalopathy were evenly represented. The 
majority of these events ensue during the induction (6, 10). 
Only in our first patient, the timing was set in the early phase 
of treatment, suggesting that both consolidation and re-
induction could present critical time points for neurotoxic 
effects of therapy. Seizure is the most common symptom, 
occurring as an isolated or combined manifestation, fol-
lowed by focal motor deficit (2, 10), the fact confirmed by all 
FIGURE 1. MRI findings of the three cases presented: case 1 – ischaemia in vascular supply of the posterior cerebral artery;  
case 2 – posterior reversible encephalopathy syndrome; case 3 – calcified microangiopathy.
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of our three cases. Although clinical presentations can be 
rather general and inconclusive, certain neurological events 
such as PRES and MLE are reproduced in a specific and rec-
ognizable clinical-radiological pattern (4). PRES is recog-
nized as a combination of clinical symptoms, including 
headache, altered mental status, seizures and visual distur-
bances, accompanied by transient subcortical white matter 
changes on T2W MRI, reflecting symmetrical vasogenic oe-
dema mostly in the parietal and occipital region. Because 
hypertension, often of secondary aetiology, is the most sig-
nificant preceding event, appropriate treatment includes 
both antiepileptic and antihypertensive therapy. Our male 
patient had a typical clinical-radiological model of PRES and 
with immediate and appropriate treatment suggested 
above, he has recovered completely, an outcome seen in 
almost 90% of affected patients (11).
Cerebrovascular accident, also referred to as stroke, is the 
most serious manifestation of cerebrovascular disease and 
one of the most severe acute neurological events that is 
broadly classified as hemorrhagic or ischaemic. Acute intra-
cerebral haemorrhage in leukemic patients occurs mainly 
due to thrombocytopenia, hyperleukocytosis or dissemi-
nated intravascular coagulation, while intracranial throm-
boembolic events are often a result of different chemother-
apy agents, including intrathecal therapy (12). Treatment 
with L-ASP, a drug causing imbalance of the pro- and anti-
coagulating systems, is considered a major risk factor for 
thrombotic events and cerebral sinovenous thrombosis 
(CSVT), particularly in the early stage of ALL treatment (4). 
CSVT appears in up to 2% of children and young adults with 
ALL, it is always symptomatic, and apart from L-ASP, is linked 
to immobility, infection and dehydration (13). Diagnosis is 
established by CT, CT or MR angiography, and treatment is 
based on anticoagulation with intensive supportive care. 
Our first patient suffered from an ischaemic insult with few 
symptoms typical for posterior circulation defect (hemipa-
resis, speech deficit), most probably as a result of L-ASP and 
concomitant steroid administration, although sepsis might 
be an additional risk factor.
Methotrexate is another important and indispensable drug 
in ALL chemotherapy regimen, administered either systemi-
cally or intrathecally, known for its acute, subacute and 
chronic neurotoxicity. The most common complication of 
intrathecally administered MTX is aseptic meningitis, less of-
ten PRES or seizures (14). Acute neurotoxicity takes place 
within 24 hours of both ways of administration and usually 
resolves by itself (11). Subacute manifestations occur up to 
two weeks after drug application and include transitory 
symptoms such as cerebrovascular insult, encephalopathy or 
convulsions (15). Postponed complication in the form of leu-
koencephalopathy, seen as white matter T2 hyperintensity, 
arises at least six months after intrathecal MTX therapy, usu-
ally is mild and asymptomatic (14). It is almost as frequently 
described on brain MRI in patients receiving intrathecal MTX 
as in those treated with cranial irradiation (16). Leukoenceph-
alopathy is a common but often accidental finding at the end 
of leukaemia treatment and successive intrathecal therapy in 
many of the symptomatic patients in our institution (study 
ongoing), as was also the case in relapsed ALL.
The most common electrolytic disturbance in general, and 
therefore also in paediatric oncology, is hyponatremia, 
which is usually iatrogenic, caused by SIADH (4). This syn-
drome occurs as a result of cytotoxic drug administration, 
such as VCR, cyclophosphamide, melphalan or cisplatin, 
and is dealt with removal of causative agent, fluid restriction 
and hypertonic saline (11). All of our patients had hypona-
tremia that was, however, in two cases mild and was cor-
rected within a few days, and therefore cannot be head-
lined as the main cause of the neurological events de-
scribed. On the other hand, the female patient with relapsed 
ALL had persistently low sodium concentrations as part of 
SIADH and most probably as a result of VCR therapy, which 
was later on one-time omitted.
Most of the acute neurological complications in ALL pa-
tients during antileukemic therapy present as emergency 
situations that require rapid identification and intervention. 
Although half of the patients are found healthy on follow-
up, CNS complications are still burdened with rather high 
morbidity and mortality, as about one-third of patients die 
or develop permanent consequences (9). Epilepsy is a long-
term sequela found in every fifth patient who suffer from 
acute CNS toxicity, mostly PRES (17). Most deaths due to 
CNS complications, interestingly, are attributed to intracra-
nial thrombosis (6). Luckily, no lethal outcome was noted in 
our patients; the more so, complete neurological recovery 
was the end-result of these three different, yet equally seri-
ous cerebral events.
To summarize, CNS manifestations are rather common 
acute developments in the first few months of ALL therapy, 
which not infrequently necessitate treatment modifications 
and have late repercussions, but are rarely fatal. Therefore, 
accurate diagnosis, prompt treatment and preferably early 
recognition of risk factors with reasonable prevention is 
 crucial.
Abbreviations:
ALL - Acute lymphoblastic leukemia
CNS - Central nervous system
IT - Intrathecal therapy
PRES - Posterior reversible encephalopathy syndrome
CT - Computed tomography
MRI - Magnetic resonance imaging
VCR - Vincristine
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L- ASP - L-asparaginase
MTX - Methotrexate
EEG - Electroencephalogram
SIADH - Syndrome of inappropriate secretion of antidiuretic hormone
MLE - Methotrexate- leukoencephalopathy
CSVT - Cerebral sino-venous thrombosis
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S A Ž E T A K
Akutna neurološka zbivanja u djece liječene  
od akutne limfoblastične leukemije
Izabela Kranjčec, Gordana Jakovljević, Nikolina Kranjec, Ana Tripalo Batoš, Lana Lončar
U nezanemarivom broju pedijatrijskih bolesnika s akutnom limfoblastičnom leukemijom komplikacije primijenjene kemoterapije i 
radioterapije uključuju akutnu neurotoksičnost, koja se može manifestirati kao cerebrovaskularna bolest, infekcija, skup nespecifič-
nih neuroloških simptoma i znakova, ili pak kao jasno definirani i prepoznatljivi kliničko - radiološki sindrom. Iako akutna neurološka 
zbivanja rijetko završavaju smrtno, najčešće je ipak riječ o hitnim stanjima koja nerijetko zahtijevaju odgodu ili promjenu terapije te 
mogu biti praćena trajnim posljedicama, poput epilepsije i kognitivne disfunkcije. Prikazujemo tri slučaja akutne neurotoksičnosti u 
djece s leukemijom liječene u našem Zavodu. Temeljem kliničke slike, laboratorijskih i radioloških nalaza okarakterizirana su kao 
moždana ishemija, sindrom posteriorne reverzibilne encefalopatije i edem mozga sa sindromom neadekvatne sekrecije antidiuret-
skog hormona. Uz pravodobnu i adekvatnu terapiju u sve troje bolesnika zamijećen je potpuni neurološki oporavak.
Ključne riječi: LEUKEMIJA, LIMFOBLASTIČNA; CENTRALNI NERVNI SISTEM; NEUROTOKSIČNOST
